Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:DRRX NASDAQ:SGMT NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$9.77+0.4%$12.38$4.88▼$19.58$212.01MN/A85,641 shs77,987 shsDRRXDURECT$1.92+1.1%$1.07$0.48▼$2.64$59.62M0.83460,793 shs416,978 shsSGMTSagimet Biosciences$7.11-3.3%$8.69$1.73▼$11.41$218.06M3.371.09 million shs479,109 shsSOPHSOPHiA GENETICS$3.61+4.9%$3.29$2.58▼$4.92$243.96M175,218 shs47,138 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+0.62%-13.59%-29.24%-7.33%+972,999,900.00%DRRXDURECT0.00%0.00%+245.45%+249.26%+42.32%SGMTSagimet Biosciences+2.37%-15.22%-23.44%+113.04%+138.64%SOPHSOPHiA GENETICS-3.91%+4.88%+0.29%+20.70%-0.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADRRXDURECT2.2979 of 5 stars0.05.00.04.44.20.00.0SGMTSagimet Biosciences3.2654 of 5 stars3.54.00.00.02.73.30.0SOPHSOPHiA GENETICS2.9123 of 5 stars3.55.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$32.80235.72% UpsideDRRXDURECT 2.00HoldN/AN/ASGMTSagimet Biosciences 3.00Buy$25.67260.99% UpsideSOPHSOPHiA GENETICS 3.00Buy$8.00121.61% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, SGMT, SOPH, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.008/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$29.007/29/2025DRRXDURECTNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/30/2025AARDAardvark TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.006/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.00(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$6.31 per shareN/ADRRXDURECT$2.03M29.37N/AN/A$0.11 per share17.45SGMTSagimet Biosciences$2M109.03N/AN/A$4.24 per share1.68SOPHSOPHiA GENETICS$65.17M3.74N/AN/A$1.13 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/ADRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%N/ASGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%N/ASOPHSOPHiA GENETICS-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)Latest DRRX, SGMT, SOPH, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AARDAardvark Therapeutics-$0.52-$0.66-$0.14-$0.66N/AN/A8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/A8/12/2025Q2 2025DRRXDURECT-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25$0.33+$0.58$0.33$17.49 million$18.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A14.0414.04DRRXDURECTN/A0.980.95SGMTSagimet BiosciencesN/A17.5517.55SOPHSOPHiA GENETICS0.623.393.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ADRRXDURECT28.03%SGMTSagimet Biosciences87.86%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ADRRXDURECT3.20%SGMTSagimet Biosciences14.70%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/ADRRXDURECT8031.05 million30.06 millionOptionableSGMTSagimet Biosciences830.67 million26.17 millionOptionableSOPHSOPHiA GENETICS52067.58 million64.28 millionNot OptionableDRRX, SGMT, SOPH, and AARD HeadlinesRecent News About These CompaniesSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 48.6% in JulyAugust 19 at 4:27 AM | marketbeat.comSOPHiA GENETICS SA: Positive Earnings Call HighlightsAugust 14, 2025 | theglobeandmail.comSOPHiA GENETICS SA (NASDAQ:SOPH) Stock Holdings Increased by Federated Hermes Inc.August 9, 2025 | marketbeat.comSOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 7, 2025 | finance.yahoo.comSophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...August 7, 2025 | finance.yahoo.comSOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlookAugust 6, 2025 | msn.comSOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSOPHiA GENETICS Reports Financial Results for Mid-2025August 5, 2025 | tipranks.comSOPHiA GENETICS Reports Second Quarter 2025 ResultsAugust 5, 2025 | prnewswire.comSOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomesAugust 5, 2025 | prnewswire.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 123.8%August 5, 2025 | marketbeat.comSOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025July 22, 2025 | prnewswire.comTurning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom IntegrationJuly 15, 2025 | pharmiweb.comPSophia Genetics launches podcast to decode data- and AI-driven medical innovationJune 27, 2025 | fiercepharma.comFAn end to an era: Supreme Court won't review IVF mixup rulingJune 26, 2025 | israelnationalnews.comIEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comFM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comZM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comTThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRRX, SGMT, SOPH, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$9.77 +0.04 (+0.41%) As of 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.DURECT NASDAQ:DRRX$1.92 +0.02 (+1.05%) As of 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Sagimet Biosciences NASDAQ:SGMT$7.11 -0.24 (-3.27%) Closing price 04:00 PM EasternExtended Trading$7.22 +0.11 (+1.48%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.SOPHiA GENETICS NASDAQ:SOPH$3.61 +0.17 (+4.94%) Closing price 04:00 PM EasternExtended Trading$3.60 -0.01 (-0.42%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access